Group 1 - The IP-SAFE project, which focuses on the development of a medical isotope drug research platform, has successfully completed the installation of its accelerator device in Lanzhou New Area, marking a significant milestone in its construction [1][3] - The project aims to achieve large-scale production of globally scarce medical alpha isotopes, specifically Actinium-225 and Radium-223, addressing China's long-term reliance on imports for these high-end medical nuclides [3] - The project is part of China's "14th Five-Year Plan" for scientific and educational infrastructure, leveraging the expertise of the Institute of Modern Physics in accelerator technology and isotope separation [3] Group 2 - The successful installation of the accelerator device is a key step towards the comprehensive completion of the IP-SAFE project, which is expected to enhance China's nuclear medicine diagnostic and therapeutic capabilities [3] - The project is set to officially launch on July 5, 2024, and its completion is anticipated to inject new momentum into the development of China's biopharmaceutical industry [3]
国家科教基础设施IP-SAFE项目加速器装置主体安装完成
Xin Hua She·2026-02-02 15:29